Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Fluvastatin; Hydrochlorothiazide; Valsartan

Criteria

Inclusion Criteria:

• Age between 40 - 65 years

• Diagnosed metabolic syndrome

• Risk of cardiovascular death ≥ 5% (according to SCORE)

• Written informed consent

Exclusion Criteria:

• Women not in menopause or not using efficient contraception

• Known hypersensitivity to study drugs

• History of ischemic heart disease